SONN — Sonnet Biotherapeutics Holdings Balance Sheet
0.000.00%
- $3.55m
- $1.49m
- $0.02m
Annual balance sheet for Sonnet Biotherapeutics Holdings, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 7.35 | 27.6 | 3.05 | 2.27 | 0.149 |
Net Total Receivables | — | — | — | 0.787 | 0.762 |
Prepaid Expenses | |||||
Total Current Assets | 7.64 | 28.8 | 5.41 | 4.74 | 2.12 |
Net Property, Plant And Equipment | 0.274 | 0.182 | 0.303 | 0.227 | 0.144 |
Other Long Term Assets | |||||
Total Assets | 7.99 | 29 | 5.83 | 5.43 | 2.77 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.72 | 6.7 | 8.16 | 5.52 | 3.21 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.97 | 6.73 | 8.37 | 5.66 | 3.26 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 3.02 | 22.3 | -2.54 | -0.226 | -0.486 |
Total Liabilities & Shareholders' Equity | 7.99 | 29 | 5.83 | 5.43 | 2.77 |
Total Common Shares Outstanding |